Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bc5c9779448a39de6c14f3d4a69ec44e0> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bc5c9779448a39de6c14f3d4a69ec44e0 NCIT_P378 "NCI" @default.
- Bc5c9779448a39de6c14f3d4a69ec44e0 type Axiom @default.
- Bc5c9779448a39de6c14f3d4a69ec44e0 annotatedProperty IAO_0000115 @default.
- Bc5c9779448a39de6c14f3d4a69ec44e0 annotatedSource NCIT_C170949 @default.
- Bc5c9779448a39de6c14f3d4a69ec44e0 annotatedTarget "The dimesylate salt of cevidoplenib, an orally available inhibitor of spleen tyrosine kinase (SYK), with potential anti-inflammatory and immunomodulating activities. Upon oral administration, cevidoplenib binds to and inhibits the activity of SYK, blocking Fc receptor and B-cell receptor (BCR)-mediated signaling in inflammatory cells, including macrophages, neutrophils, mast cells, natural killer (NK) cells and B-cells. This leads to the inhibition of the activation of these inflammatory cells, and the related inflammatory responses and tissue damage. SYK, a non-receptor cytoplasmic protein tyrosine kinase widely expressed in hematopoietic cells, plays a key role in Fc receptor and B-cell receptor signaling in inflammatory cells. It is involved in coupling activated immunoreceptors, such as Fc receptors and B-cell receptors, to signal downstream events that mediate diverse cellular responses, including proliferation, differentiation, and phagocytosis, which are important for allergic and antibody-mediated immune diseases such as immune thrombocytopenia (ITP)." @default.